Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.60 |
| ▸ | GALR2 | O43603 | 1/20 | 0.60 |
| ▸ | MITF | O75030 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | XBP1 | P17861 | 1/20 | 0.60 |
| ▸ | CCR6 | P51684 | 1/20 | 0.60 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | FLT1 | P17948 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14854666 | 0.94 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2NPSR1GALR2MITF | |
| SCHEMBL5167381 | 0.86 | SMN1; SMN2 (0.52) | ALDH1A1SMN1; SMN2NPSR1GALR2MITF | |
| SCHEMBL13088438 | 0.84 | SMN1; SMN2 (0.64) | ALDH1A1SMN1; SMN2NPSR1GALR2MITF | |
| SCHEMBL32659715 | 0.84 | PDGFRB (0.51) | ALDH1A1SMN1; SMN2NPSR1GALR2MITF | |
| SCHEMBL5167860 | 0.83 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2NPSR1GALR2MITF | |
| SCHEMBL2309925 | 0.82 | LMNA (0.50) | ALDH1A1SMN1; SMN2NPSR1GALR2MITF | |
| SCHEMBL1560111 | 0.82 | PDGFRB (0.47) | ALDH1A1SMN1; SMN2LMNAKMT2AMAPT | |
| SCHEMBL18038909 | 0.82 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2NPSR1GALR2MITF | |
| SCHEMBL7474176 | 0.81 | LMNA (0.60) | ALDH1A1SMN1; SMN2NPSR1GALR2MITF | |
| SCHEMBL26631746 | 0.81 | NPSR1 (0.60) | ALDH1A1SMN1; SMN2NPSR1GALR2MITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299085-B2 | Quinazoline derivatives | NOVARTIS AG (CH) | 2012-10-30 | — | — | US | disclosed |
| US-8299085-B2 | Quinazoline derivatives | NOVARTIS AG (CH) | 2012-10-30 | — | — | US | disclosed |
| US-8299085-B2 | Quinazoline derivatives | NOVARTIS AG (CH) | 2012-10-30 | — | — | US | disclosed |
| US-20070208018-A1 | Quinazoline Derivatives | NOVARTIS AG (CH) | 2007-09-06 | — | — | US | disclosed |
| US-20070208018-A1 | Quinazoline Derivatives | NOVARTIS AG (CH) | 2007-09-06 | — | — | US | disclosed |
| US-20070208018-A1 | Quinazoline Derivatives | NOVARTIS AG (CH) | 2007-09-06 | — | — | US | disclosed |
| EP-1773788-A2 | QUINAZOLINE DERIVATIVES | NOVARTIS-PHARMA GMBH (AT) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006010591-A2 | QUINAZOLINE DERIVATIVES | NOVARTIS AG (CH) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208018-A1 | Quinazoline Derivatives | CYP3A5, CYP3A7, CYP3A4 | ALDH1A1 460/4885SMN1; SMN2 3684/4885NPSR1 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.